Clinical trial NCT04358055: Investigation to Evaluate the Clinical Safety and Effectiveness of WET® Gel
Official title: Open-label, Multicenter, Prospective Investigation to Evaluate the Clinical Safety and Effectiveness of WET® Gel, Containing Hydeal-D®, an Ester of Hyaluronic Acid, in the Treatment of Nasal Dryness
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nose Dry Feeling of
Keywords: dryness
nasal
gel
hyaluronic acid
Lead sponsor: Fidia Farmaceutici s.p.a.
Sponsor class: INDUSTRY
First posted: 2020-04-22
Enrollment: 58
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The objective of the investigation is to assess the clinical safety and effectiveness of WET® gel in the treatment of nasal dryness, following maximum two weeks of treatment.

Detailed description: The objective of the project is to perform a post marketing clinical study to confirm safety and clinical effectiveness of WET® gel in the treatment of nasal dryness.

This investigation will be carried out following the CE marking of the WET® gel device and is mainly intended to answer questions relating to clinical safety or performance (i.e. residual risks) of the device when used in accordance whit its approved labelling.

The study is also aimed at defining the optimal dose regimen of WET® gel.

Eligibility criteria: Inclusion Criteria:

1. Patients having undergone the informed consent process and having signed an approved consent form;
2. Male and female outpatients, aged ≥ 18 years;
3. Patients with nasal dryness of moderate-severe intensity, defined as a score ≥ 4 in a 0-10 numeric rating scale (NRS), with or without superficial microlesions;
4. Patients with absence of nasal discharge;
5. Patients having not taken oral or intranasal decongestants, antihistamines (by any route), corticosteroids (by any route), intranasal anticholinergics, leukotriene inhibitors, mucolytics (by any route), sodium cromoglycate (by any route) in the 4 weeks preceding the screening/baseline visit and agree not to take them during the investigation;
6. Patients with a cooperative attitude and ability to be trained to use correctly the investigational medical device, to adhere to the dosing and visit schedules, and agree to record symptoms' severity scores and use of the investigational device in a daily diary;
7. If female of child-bearing potential, they must have a negative urine pregnancy test at the screening visit and use a reliable form of contraception for a least 1 month prior to Screening and throughout the investigation. Note: to be considered females of non-child-bearing potential, females must be surgically sterile or postmenopausal as documented in medical history for at least 1 year.

Exclusion Criteria:

1. Patients with atopic or non-atopic rhinosinusitis in active phase;
2. Patients with anatomical abnormalities of the nose (turbinate hypertrophy, septal deviation, polyps) that would interfere with nasal airflow;
3. Patients with a medical history of nasal or sinus surgery in the previous 12 months;
4. Patients with upper respiratory tract or sinus infection;
5. Patients with rhinitis medicamentosa;
6. Patients with epistaxis;
7. Patients having received treatment with oral or intranasal decongestants, anti-histamines (by any route), corticosteroids (by any route), intranasal anticholinergics, leukotriene inhibitors, mucolytics (by any route), sodium cromoglycate (by any route) in the 4 weeks preceding the screening/baseline visit;
8. Patients having received treatment with antibiotics (by any route) in the 4 weeks preceding the screening/baseline visit;
9. Patients currently undergoing a progressive course of immunotherapy(hyposensitization);
10. Patients having performed a sinus lavage in the 2 weeks preceding the screening/baseline visit;
11. Patients with known or suspected allergy, hypersensitivity or intolerance to hyaluronic acid and/or any other component of the investigational device;
12. Patients with presence of any of the following clinical conditions: active or quiescent tuberculosis infection of the respiratory tract, untreated fungal, bacterial, systemic viral infections or ocular herpes simplex;
13. Patients with presence of other serious gastrointestinal, renal, hepatic, pulmonary, cardiovascular, or neurological disease that could interfere with the outcome of the investigation or the patient's ability to comply with investigation requirements;
14. Patients who have been diagnosed of cancer within the past 5 years (except for successfully treated basal and squamous cell carcinomas);
15. Pregnant (positive urine test) or breastfeeding women, or planning to become pregnant during the investigation;
16. Patients with history of alcoholism or drug dependence;
17. Patients unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the investigation;
18. Patients who have used any investigational drug or device, or have participated in an investigational protocol in the past 3 months;
19. Patients who have been previously enrolled in this investigation.

Primary outcomes:
measure: General safety and tolerability of WET® gel
timeFrame: 15 days (the entire study duration)
Secondary outcomes:
measure: Change in nasal dryness
timeFrame: 15 days (the entire study duration)
measure: Percentage of patients with resolution of nasal dryness
timeFrame: 15 days (the entire study duration)
measure: Time to resolution of nasal dryness
timeFrame: 15 days (the entire study duration)
measure: Changes from baseline of nasal crusting
timeFrame: 15 days (the entire study duration)
measure: Changes from baseline of nasal itching
timeFrame: 15 days (the entire study duration)
measure: Changes from baseline of nasal burning
timeFrame: 15 days (the entire study duration)
measure: Changes from baseline of nasal obstruction
timeFrame: 15 days (the entire study duration)
measure: Compliance to treatment with WET® gel
timeFrame: 15 days (the entire study duration)
Other outcomes:
Locations:
city: Como
country: Italy
facility: ATS Insubria
state: Via Varese 11
city: Alzate Brianza
country: Italy
facility: ATS Insubria
city: Erba
country: Italy
facility: ATS Insubria
city: Porlezza
country: Italy
facility: ATS Insubria
Study officials:
affiliation: Fidia Farmaceutici s.p.a.
name: Nicola Giordan
role: STUDY_DIRECTOR
References: